TABLE 1

Liver and plasma metabolic parameters in mice fed standard diet or high-fat diet and treated with vehicle, FGF21, and rosiglitazone

ParametersStandard dietHigh-fat diet
VehicleVehicleFGF21Rosiglitazone
0.1 mg/kg1 mg/kg10 mg/kg
Body weight (g)*32.6 ± 1.2†49.1 ± 0.851.2 ± 0.946.1 ± 1.138.0 ± 1.0†56.2 ± 2.1†
Liver weight (g)*1.5 ± 0.1†2.5 ± 0.21.9 ± 0.21.5 ± 0.11†1.2 ± 0.5†2.9 ± 0.14
Liver triglyceride (mg/g)*10 ± 2.5†154 ± 13.4103 ± 27.5‡47 ± 2.5†23 ± 1.5†212 ± 6.6§
Liver cholesterol (mg/g)*1.6 ± 0.1†6.4 ± 1.04.1 ± 1.0‡1.6 ± 0.1†1.7 ± 0.1†6.7 ± 0.5
Gastrocnemic muscle weight (g)*0.36 ± 0.010.38 ± 0.020.39 ± 0.010.37 ± 0.010.35 ± 0.010.37 ± 0.01
Muscle triglyceride (mg/g)*16 ± 1.7†65 ± 6.664 ± 1160 ± 7.537 ± 4.6‡90 ± 15
Muscle cholesterol (mg/g)*1.1 ± 0.061.7 ± 0.41.7 ± 0.41.3 ± 0.071.1 ± 0.052.1 ± 0.4
Plasma ALT (units/l)¶25 ± 2.6†248 ± 69.782 ± 16.6§44 ± 4.5†30 ± 5.4†142 ± 32.7‡
Plasma AST (units/l)¶49 ± 4.6†205 ± 48102 ± 17§81 ± 6.5†69 ± 7.6†128 ± 17.6‡
Plasma ALP (units/l)¶54 ± 1.5‡71 ± 8.745 ± 3.1§33 ± 3.8†30 ± 2†81 ± 7.2
Plasma glucagon (pg/ml)¶305 ± 88280 ± 63379 ± 118204 ± 33236 ± 35250 ± 48
Plasma β-hydroxyburate (nmol/l)*0.62 ± 0.07§0.85 ± 0.050.84 ± 0.040.58 ± 0.06§0.61 ± 0.05§0.56 ± 0.05§
  • Data are means ± SE. DIO mice were treated with recombinant murine FGF21 intraperitoneally at doses of 0 (vehicle), 0.1, 1, or 10 mg · kg−1 · day−1. An additional group of DIO mice was treated with rosiglitazone formulated in the high-fat diet to provide a dose of ∼4 mg · kg−1 · day−1. Mice on normal standard diet were included as controls and were injected intraperitoneally with vehicle.

  • * Measurements that were conducted on day 42 (n = 5/group) or day 24 (n = 10/group) after the initiation of the treatments, respectively.

  • Measurements that were conducted on day 42 (n = 5/group) or day 24 (n = 10/group) after the initiation of the treatments, respectively.

  • P < 0.05,

  • § P < 0.01,

  • P < 0.001 vs. vehicle-treated DIO mice.